{"analyses":[{"ciLowerLimit":"0.37","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.78","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0010","paramType":"Hazard Ratio (HR)","paramValue":"0.54","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2598","paramType":"Hazard Ratio (HR)","paramValue":"0.80","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to low number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to low number of events.","groupId":"OG001","lowerLimit":"21.4","upperLimit":"NA","value":"36.9"},{"groupId":"OG002","lowerLimit":"18.6","upperLimit":"26.5","value":"23.1"},{"groupId":"OG003","lowerLimit":"11.1","upperLimit":"35.9","value":"15.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"93"},{"groupId":"OG003","value":"91"}],"units":"Participants"}],"description":"DFS was defined as the time from randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks","id":"OG000","title":"Cohort 1 Vemurafenib"},{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"OG001","title":"Cohort 1 Placebo"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks","id":"OG002","title":"Cohort 2 Vemurafenib"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"OG003","title":"Cohort 2 Placebo"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants enrolled in the study, whether or not they had received study medication.","reportingStatus":"POSTED","timeFrame":"From randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause (up to the April 17, 2017 data cut-off, approximately 4.5 years)","title":"Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT)","type":"PRIMARY","unitOfMeasure":"months"}